Alveofact inhalation vapour

Marketed by Dexa Medica

Ingredients in every vial

Phospholipid fraction from bovine lung (surfactant) 54 mg

Each package contains

1 vial of 54 mg

Other details

Dosage form:Inhalation vapour; powder
Flavour: None

W.H.O. classification

ATC Level 1: R - Respiratory system
ATC Level 2: R07 - Other Respiratory System Products in ATC
ATC Level 3: R07A - Other Respiratory System Products in ATC

Warnings

Pregnancy

CONSULT YOUR DOCTORSafety of this item for use during pregnancy has not been established. Please consult your doctor.

Lactation

CONSULT YOUR DOCTORSafety of this item for use during lactation has not been established. Please consult your doctor.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Available in

Indonesia
The Philippines

Dosage information

OTHER DETAILS
NEONATUS
Each dose of Alveofact is 54 mg of total phospholipids per kg body weight (1.2 ml per kg body weight).
Prevention: A single dose of Alveofact and application within the first hour after birth are recommended.
Treatment: Alveofact should be administered early in the course of RDS i.e preferably less than 6 hours of age.
Treatment with Alveofact is given only by endotracheopulmonary instillation. A ready prepared catheter (e.g. umbilical catheter or gastric tube) is inserted through the positioned tracheal tube and the catheter opening positioned at the level of the tip of the tube. Using a syringe, the single dose of 1.2 ml Alveofact per kg body weight (corresponding to 54 mg total phospholipids per kg body weight) is administered as an intratracheal bolus via this catheter.
Additional injections of air are used to help ensure that instillation is complete. Upon removal of the catheter, the patient is reconnected to the respirator. To promote the equal distribution of Alveofact, the patient may be gently turned from side to side every few seconds.
Duration of treatment: Depending on the need for ventilation and on the initial dose, the following dosing scheme should be applied: Initial dose 54 mg: up to three subsequent applications of 54 mg.
Initial dose 108 mg: up to one dose of 108 mg or up to two doses of 54 mg.
The total dose should not exceed 216 mg total phospholipids per kg body weight within the first 2 days of life.

Indication

For treatment of respiratory distress syndrome (RDS) in neonates

Disclaimer

The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.